<DOC>
	<DOC>NCT02111928</DOC>
	<brief_summary>This observational pilot-study is intended to collect outcome data from a cohort of 30 patients suffering from hyper-evaporative dry eye disease who are treated with the medical device NovaTears® eye drops for a duration of 5 to 7 weeks.</brief_summary>
	<brief_title>NovaTears® Eye Drops Observational Study</brief_title>
	<detailed_description />
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>According to NovaTears® instruction for use ≥ 18 years Patients with mild to moderate disease and hyperevaporative dry eye disease applying eye lid hygiene for at least 14 days Ability and willingness to provide written Informed Consent Ability and willingness to participate in all examinations Willingness and ability to return for follow up visit Patients with hypersensitivity to any of the components of NovaTears® Patients with contact lenses, pregnancies, or who are breast feeding Patients with non evaporate dry eye disease Patients taking lipid containing eye drops or requiring pharmacologic treatment of dry eye disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>